LEXEO Therapeutics
Reinaldo Diaz is a venture Partner of Longitude Capital. concurrently, Mr. Diaz serves as the Chief Business officer of opna-I0, a Longitude portfolio company, as well as a consultant for various companies in the healthcare industry, including Auven Therapeutics, where he previously served as Managing Director from 2008 to 2018. Prior to joining Auven Therapeutics, he was a Managing Member and co-founder of Diaz & Altschul Capital Management (D&A Capital). Prior to founding D&A Capital, Mr. Diaz was a Managing Director and Head of the Healthcare group at Schroder Wertheim & Co. Mr. Diaz started his career at PaineWebber, where he was a key member of the PaineWebber Healthcare Investment Banking Group and President of PaineWebber Development Corporation. He currently serves on the board of Inozyme (INZY). Mr. Diaz holds an MBA from Harvard Business school and a BA from Harvard University.
This person is not in the org chart
This person is not in any offices
LEXEO Therapeutics
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine.